The research-use-only panel expands from 58 to 80 gene targets and is designed to detect long and multiple FLT3-ITDs within a single sequencing workflow.
Pillar Biosciences has launched the oncoReveal Myeloid v2 Panel, an expanded research-use-only DNA next-generation sequencing (NGS) panel designed for myeloid malignancies.
The updated panel expands the company’s original myeloid assay from 58 to 80 gene targets and enhances the detection of FLT3 internal tandem duplications (ITDs), including long and multiple ITDs that have traditionally presented technical challenges for NGS platforms.
Preserving Established Workflows
Building on the previous 58-gene design, the oncoReveal Myeloid v2 adds 22 genes while retaining all prior targets. This configuration is designed to give laboratories broader, guideline-relevant coverage without altering existing laboratory protocols.
To accommodate the additional content, only four of the original 766 amplicons covering the initial 58 genes were modified. Pillar attributes this panel design to its proprietary SLIMamp chemistry and VersaTile primer design tool, which allow panel scaling while maintaining the analytical performance of the original content.
“With oncoReveal Myeloid v2, we significantly expanded our myeloid gene content while preserving the trusted panel content laboratories already rely on,” says ShiPing Zou, senior director, product management at Pillar Biosciences, in a release. “We also invested significant effort in FLT3-ITD detection so laboratories can obtain accurate, base-pair-resolved calls for long and multiple ITDs without defaulting to a separate fragment-analysis workflow.”
Addressing Analytical Challenges in FLT3-ITD Detection
A central capability of the updated panel is the detection of long (300+ base pair) and multiple FLT3-ITDs using standard 2 x 150 sequencing.
These variant types have historically challenged short-read NGS platforms, often requiring clinical research laboratories to perform secondary fragment-analysis testing to confirm duplication length and presence. The v2 panel allows users to identify these alterations within a single sequencing workflow.
The full updated gene list for the panel is available on the company’s website at launch.
